US Patent

US11357859 — Compositions for the treatment of gastrointestinal inflammation

Method of Use · Assigned to Viropharma Biologics LLC · Expires 2028-11-12 · 2y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating, preventing, or alleviating gastrointestinal inflammation and symptoms associated with inflammatory diseases of the gastrointestinal tract.

USPTO Abstract

Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Drugs covered by this patent

Pulmicort Respules (BUDESONIDE) · AstraZeneca K.K.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3820`	—	Pulmicort Respules

Patent Metadata

Patent number: US11357859
Jurisdiction: US
Classification: Method of Use
Expires: 2028-11-12
Drug substance claim: No
Drug product claim: No
Assignee: Viropharma Biologics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.